Reproductive BioMedicine Online
Volume 19, Issue 5 , Pages 685-694, November 2009

Cystic fibrosis transmembrane conductance regulator mutations in azoospermic and oligospermic men and their partners

  • Sabina Gallati

      Affiliations

    • Division of Human Genetics, Departments of Paediatrics and Clinical Research, Inselspital, University of Berne, CH-3010 Berne, Switzerland
    • Corresponding Author InformationCorrespondence:
  • ,
  • Simone Hess

      Affiliations

    • Division of Human Genetics, Departments of Paediatrics and Clinical Research, Inselspital, University of Berne, CH-3010 Berne, Switzerland
  • ,
  • Dorothea Galié-Wunder

      Affiliations

    • Division of Gynaecological Endocrinology and Reproductive Medicine, Inselspital, University of Berne, CH-3010 Berne, Switzerland
  • ,
  • Elisabeth Berger-Menz

      Affiliations

    • Division of Obstetrics and Gynaecology, Lindenhofspital, CH-3001 Berne, Switzerland
  • ,
  • Dominik Böhlen

      Affiliations

    • Division of Urology, Clinic Beau-Site, CH-3013 Berne, Switzerland

Received 3 November 2008; received in revised form 20 January 2009; accepted 1 June 2009. published online 02 August 2010.

Declaration: The authors report no financial or commercial conflicts of interest.

Abstract 

The objective of this study was to investigate the contribution of cystic fibrosis transmembrane conductance regulator (CFTR) to human infertility and to define screening and counselling procedures for couples asking for assisted reproduction treatment. Extended CFTR mutation screening was performed in 310 infertile men (25 with congenital absence of the vas deferens (CAVD), 116 with non-CAVD azoospermia, 169 with severe oligospermia), 70 female partners and 96 healthy controls. CFTR mutations were detected in the majority (68%) of CAVD patients and in significant proportions in azoospermic (31%) and oligospermic (22%) men. Carrier frequency among partners of infertile men was 16/70, exceeding that of controls (6/96) significantly (P=0.0005). Thus, in 23% of infertile couples both partners were carriers, increasing the risk for their offspring to inherit two mutations to 25% or 50%. This study emphasizes the necessity to offer extended CFTR mutation screening and counselling not only to patients with CAVD but also to azoospermic and oligozoospermic men and their partners before undergoing assisted reproduction techniques. The identification of rare and/or mild mutations will not be a reason to abstain from parenthood, but will allow adequate treatment in children at risk for atypical or mild cystic fibrosis as soon as they develop any symptoms.

Keywords: assisted reproduction, cystic fibrosis transmembrane conductance regulator, mutation spectrum, polyvariant mutants, primary infertility, risk for offspring

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Sabina Gallati graduated in Biology and Genetics from the University of Berne. She has undertaken postdoctoral research and training in molecular genetics and forensics in London (UK), Würzburg (Germany), Boston (USA) and Quantico (USA) and has specialised in Medical Genetic Analysis. In 2003, she became Professor of Human Genetics and Head of the Division of Human Genetics at the Medical Faculty of the University of Berne. Her main research interests are genetic mechanisms in Cystic Fibrosis and CFTR-related disorders, hereditary haemochromatosis and mitochondriopathies. Dr Sabina Gallati

PII: S1472-6483(09)00066-2

doi:10.1016/j.rbmo.2009.09.002

Reproductive BioMedicine Online
Volume 19, Issue 5 , Pages 685-694, November 2009